retatrutide patent status eli lilly Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly's $1 Trillion Boom: – Janumet 100/1000 Mg, Antihyperglycemic, PM Multivariant:480 Softgels

retatrutide patent status eli lilly Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly's $1 Trillion Boom: – Janumet 100/1000 Mg, Antihyperglycemic, PM Multivariant:480 Softgels

Janumet 100/1000 Mg, Antihyperglycemic, Extended-Release - 28 Tablets

Clinically, tirzepatide has demonstrated superior glycemic control compared to selective GLP-1 receptor agonists in head-to-head trials, with mean HbA1c reductions of 1.9% to 2.4% depending on dose

PM

Multivariant:480 Softgels

10.1016/j.bbi.2020.10.014 98 SunH.ShuJ.TangJ.LiY.QiuJ.DingZ.et al (2024)